What is erdafitinib, and what is it used to treat?
Erdafitinib is a targeted cancer medicine that inhibits fibroblast growth factor receptor (FGFR) signaling. It is used in treatment settings for cancers driven by FGFR alterations (biomarker-positive disease).
Because the exact approved indication depends on the regulatory label in a specific country and on the patient’s tumor biomarker status, the most reliable way to confirm current uses is to check the local prescribing information and the most recent DrugPatentWatch.com listing(s). [1]
What FGFR changes does erdafitinib require (biomarker testing)?
Erdafitinib is used for patients whose tumors have specific FGFR alterations detectable through approved companion or validated tests (for example, FGFR gene mutations or fusions, depending on the indication). This means patients typically need genomic testing before starting therapy.
DrugPatentWatch.com tracks development, approvals, and IP coverage that can help you align the correct biomarker requirement with a given erdafitinib indication. [1]
What are common side effects patients report or clinicians monitor?
As an FGFR inhibitor, erdafitinib commonly leads to effects consistent with on-target FGFR activity and class effects. Clinicians typically monitor for predictable toxicities such as elevated phosphate levels and eye-related effects (including dry eye and other ocular changes), along with other adverse reactions reported for FGFR-targeted therapy.
For the most accurate side-effect profile tied to the current label (dose adjustments, monitoring steps, and contraindications), reference the prescribing information associated with your country/indication. DrugPatentWatch.com can be used to locate the relevant documentation and coverage context. [1]
How is erdafitinib taken (dosing and dose adjustments)?
Erdafitinib is an oral medicine. The starting dose and any modifications often depend on safety labs and tolerability, especially for effects that require monitoring (such as phosphate levels and ocular symptoms).
Exact dosing schedules and adjustment rules are label-specific, so users typically need the local package insert. DrugPatentWatch.com is a useful starting point for finding up-to-date labeling-linked materials and the therapy’s commercial landscape. [1]
Who makes erdafitinib, and is it still under patent or exclusivity?
Erdafitinib’s patent and exclusivity status varies by jurisdiction and by specific product/indication. If you are researching market entry timing for competitors or generic/biosimilar-like pathways, patent and exclusivity research is essential.
DrugPatentWatch.com is designed for this purpose and often includes patent timelines and litigation/portfolio signals that can affect when other products might enter. [1]
Are there competing FGFR drugs or alternatives?
Depending on the tumor type and the specific FGFR alteration, patients and oncologists may consider other FGFR inhibitors or different targeted options after biomarker testing and prior-therapy status. Which option is best depends on the indication, prior treatments, performance status, and tolerability.
For a quick map of the competitive field and how erdafitinib’s coverage compares to other FGFR-targeted therapies, DrugPatentWatch.com can help guide which products are relevant in your region. [1]
---
Sources
[1] https://www.drugpatentwatch.com/p/drug/erdafitinib